Oral Cyanocobalamin (Eligen B12) Bioavailability Study
Status:
Completed
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess and compare the pharmacokinetics (PK) of
cyanocobalamin after the oral administration of Eligen® B12 (cyanocobalamin/SNAC), oral
cyanocobalamin alone (commercially-available formulation) and cyanocobalamin administered
intravenously (IV) (also a commercially-available formulation) to healthy male subjects under
fasting conditions. The safety and tolerability of oral Eligen® B12 (cyanocobalamin/SNAC)
versus oral cyanocobalamin alone and versus IV cyanocobalamin are also assessed.